Research Feed
ACLX — Gilead Acquisition: Post-Mortem & Pattern Extraction
Verdict: NO POSITION. Deal announced Feb 23, 2026. Alpha window closed. LR Signal: 1.0 — No divergence from market pricing. The deal IS the price. Arb carry of 1-2% over 2-3 months is available but outside our edge zone. Gilead Sciences bid $115/share cash + $5 CVR (non-transferable) for Arcellx, an